{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:33:25Z","timestamp":1782272005005,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100009553","name":"Agentura Pro Zdravotnick\u00fd V\u00fdzkum \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.cmi.2019.08.004","type":"journal-article","created":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T02:09:30Z","timestamp":1565748570000},"page":"207-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial"],"prefix":"10.1016","volume":"26","author":[{"given":"F.","family":"Rob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Klubalov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ny\u010dov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hercogov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Unemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2019.08.004_bib1","series-title":"Report on global sexually transmitted infection surveillance, 2018","author":"World Health Organization (WHO)","year":"2018"},{"key":"10.1016\/j.cmi.2019.08.004_bib2","unstructured":"European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases. http:\/\/atlas.ecdc.europa.eu\/public\/index.aspx."},{"key":"10.1016\/j.cmi.2019.08.004_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40471-017-0094-z","article-title":"Gonorrhea","volume":"4","author":"Bowen","year":"2017","journal-title":"Curr Epidemiol Rep"},{"key":"10.1016\/j.cmi.2019.08.004_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002344","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action","volume":"14","author":"Wi","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.cmi.2019.08.004_bib5","doi-asserted-by":"crossref","DOI":"10.1071\/SH19023","article-title":"The WHO Global Gonococcal Antimicrobial Surveillance Programme (WHO GASP) \u2013 international collaborative actions and enhanced research efforts essential","author":"Unemo","year":"2019","journal-title":"Sex Health"},{"key":"10.1016\/j.cmi.2019.08.004_bib6","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2015","volume":"64","author":"Workowski","year":"2015","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.cmi.2019.08.004_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/0956462412472837","article-title":"2012 European guideline on the diagnosis and treatment of gonorrhoea in adults","volume":"24","author":"Bignell","year":"2013","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.cmi.2019.08.004_bib8","series-title":"WHO guidelines for the treatment of Neisseria gonorrhoeae","author":"World Health Organization (WHO)","year":"2016"},{"key":"10.1016\/j.cmi.2019.08.004_bib9","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/S1473-3099(17)30310-9","article-title":"Sexually transmitted infections: challenges ahead","volume":"17","author":"Unemo","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2019.08.004_bib10","series-title":"British Association for Sexual Health and HIV national guideline for the management of infection with Neisseria gonorrhoeae","author":"Fifer","year":"2019"},{"key":"10.1016\/j.cmi.2019.08.004_bib11","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.47.1800617","article-title":"Multidrug-resistant Neisseria gonorrhoeae isolate, belonging to the internationally spreading Japanese FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin in Ireland, August 2018","volume":"23","author":"Golparian","year":"2018","journal-title":"Euro Surveill"},{"key":"10.1016\/j.cmi.2019.08.004_bib12","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2019.24.10.1900147","article-title":"Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018","volume":"24","author":"Eyre","year":"2019","journal-title":"Euro Surveill"},{"key":"10.1016\/j.cmi.2019.08.004_bib13","doi-asserted-by":"crossref","DOI":"10.3201\/eid2404.171873","article-title":"Cooperative recognition of internationally disseminated ceftriaxone-resistant ceftriaxone-resistant Neisseria gonorrhoeae strain","volume":"24","author":"Lahra","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2019.08.004_bib14","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.27.1800323","article-title":"Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018high-level azithromycin resistance, England, February 2018","volume":"23","author":"Eyre","year":"2018","journal-title":"Euro Surveill"},{"key":"10.1016\/j.cmi.2019.08.004_bib15","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1473-3099(18)30340-2","article-title":"Genetic characterization of Neisseria gonorrhoeae resistant to both ceftriaxone and azithromycin","volume":"18","author":"Whiley","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2019.08.004_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002366","article-title":"Multidrug-resistant gonorrhea: a research and development roadmap to discover new medicines","volume":"14","author":"Alirol","year":"2017","journal-title":"PLoS Med"},{"key":"10.1016\/j.cmi.2019.08.004_bib17","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/cid\/ciu521","article-title":"The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea","volume":"59","author":"Kirkcaldy","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.08.004_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00007435-199501000-00007","article-title":"Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important?","volume":"22","author":"Moran","year":"1995","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.cmi.2019.08.004_bib19","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/apm.12440","article-title":"Analytical specificity and sensitivity of the novel dual-target GeneProof Neisseria gonorrhoeae PCR kit for detection of N.\u00a0gonorrhoeae","volume":"123","author":"Golparian","year":"2015","journal-title":"APMIS"},{"key":"10.1016\/j.cmi.2019.08.004_bib20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1128\/CMR.00010-14","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae in the 21st Century: past, evolution, and future","volume":"27","author":"Unemo","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2019.08.004_bib21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/OLQ.0000000000000693","article-title":"Susceptibility of Neisseria gonorrhoeae to gentamicin-gonococcal isolate surveillance project, 2015\u20132016","volume":"45","author":"Mann","year":"2018","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.cmi.2019.08.004_bib22","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/jac\/dkq476","article-title":"An evaluation of gentamicin susceptibility of Neisseria gonorrhoeae isolates in Europe","volume":"66","author":"Chisholm","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.08.004_bib23","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1186\/s12879-018-3528-4","article-title":"Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016","volume":"18","author":"Day","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2019.08.004_bib24","first-page":"142","article-title":"Effectiveness of gentamicin for gonorrhoea treatment: systematic review and meta-analysis","volume":"89","author":"Dowell","year":"2013","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.cmi.2019.08.004_bib25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/2046-4053-3-104","article-title":"The effectiveness of gentamicin in the treatment of Neisseria gonorrhoeae: a systematic review","volume":"3","author":"Hathorn","year":"2014","journal-title":"Syst Rev"},{"key":"10.1016\/j.cmi.2019.08.004_bib26","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/S0140-6736(18)32817-4","article-title":"Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial","volume":"393","author":"Ross","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2019.08.004_bib27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bcp.13439","article-title":"Adverse effects of a single dose of gentamicin in adults: a systematic review","volume":"84","author":"Hayward","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2019.08.004_bib28","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/jac\/dky548","article-title":"Pharmacokinetic considerations regarding the treatment of bacterial sexually transmitted infections with azithromycin: a review","volume":"74","author":"Kong","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.08.004_bib29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/OLQ.0000000000000088","article-title":"Comparing azithromycin and doxycycline for the treatment of rectal chlamydial infection: a retrospective cohort study","volume":"41","author":"Khosropour","year":"2014","journal-title":"Sex Transm Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19304434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19304434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:25:02Z","timestamp":1761117902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X19304434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1198743X19304434"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2019.08.004","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2019.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}